Cannabidiol is a Small Molecule owned by Jazz Pharmaceuticals, and is involved in 83 clinical trials, of which 59 were completed, 19 are ongoing, and 5 are planned.

Cannabidiol (Epidiolex) acts as a competitive antagonist at the G-protein coupled receptor, GPR55, inhibiting binding of a membrane phospholipid, lysophosphatidylinositol (LPI). LPI increases the excitatory or inhibitory ratio in hippocampal neuronal networks by a dual mechanism by enhancing excitatory transmission and by attenuating inhibition. The drug candidate by opposing LPI action blocks LPI- mediated increases in presynaptic Ca2+ and vesicular release, thus reducing excitability at axon terminals. On blocking GPR55, it exerts anti-seizure effects on both excitatory and inhibitory synapses through actions. TRPV1 is a calcium-permeable channel and mediator of epilepsy in the hippocampus. The drug candidate by down regulating TRPV1 receptor helps in alleviating the disease.

The revenue for Cannabidiol is expected to reach a total of $19.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Cannabidiol NPV Report.

Cannabidiol is currently owned by Jazz Pharmaceuticals.

Cannabidiol Overview

Cannabidiol (Epidiolex/ CBD, Epidyolex) is a phytocannabinoid, one of the active cannabinoid identified within the Cannabis plant accounting for up to 40% of the Cannabis plant's extract, acts as an anti-epileptic agent. It is formulated as a solution for oral route of administration. Epidiolex is indicated for the treatment of seizures associated with Lennox-gastaut syndrome or dravet syndrome in patients 2 years of age and older and Rett syndrome and also as an adjunctive therapy of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of age and older or it is also indicated for tuberous sclerosis complex (TSC) in patients 1 year of age and older. Cannabidiol (Epidiolex) is under development for the treatment of electrical status epilepticus of sleep (ESES), tuberous sclerosis complex in patients age 1 month to less than 12 months, epilepsy with myoclonic atonic seizures, Lennox-Gastaut syndrome (LGS) Dravet syndrome, blepharospasm, schizophrenia, autism spectrum disorder (pervasive developmental disorder), tuberous sclerosis complex, anorexia nervosa, Sturge-Weber syndrome, infantile spasm, tremor in Parkinson's Disease, heroin use disorder, opioid use disorder, neonatal hypoxic-ischemic encephalopathy (NHIE), developmental and epileptic encephalopathy. It was under development for Rett syndrome and schizophrenia related psychotic disorder.

Jazz Pharmaceuticals Overview

Jazz Pharmaceuticals is a specialty biopharmaceutical company which identifies, develops, and commercializes medicines with focus on narcolepsy, cancer, pain, and psychiatry. Its marketed products include Xyrem (sodium oxybate) oral solution, Sunosi (solriamfetol), Defitelio (defibrotide sodium), Erwinaze (asparaginase erwinia chrysanthemi), Vyxeos (daunorubicin and cytarabine) liposome for injection, and others. The company also has various pipeline product candidates related to focus areas such as sleep, neurological disorders, hematology, and oncology including hematologic malignancies and solid tumors. The company sells its products through a network of local distributors and wholesalers. It has operations in the US and Europe. Jazz Pharmaceuticals is headquartered in Dublin, Ireland.

The company reported revenues of (US Dollars) US$3,094.2 million for the fiscal year ended December 2021 (FY2021), an increase of 30.9% over FY2020. In FY2021, the company’s operating margin was 5.5%, compared to an operating margin of 15.8% in FY2020. The net loss of the company was US$329.7 million in FY2021, compared to a net profit of US$238.6 million in FY2020. The company reported revenues of US$940.7 million for the third quarter ended September 2022, an increase of 0.8% over the previous quarter.

Quick View – Cannabidiol

Report Segments
  • Innovator (NME)
Drug Name
  • Cannabidiol
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Gastrointestinal
  • Genetic Disorders
  • Metabolic Disorders
  • Ophthalmology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.